Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV. A Randomized Controlled Crossover Study

Comunity health actions are set up in populations of women aged 30 to 65 in vulnerable situations living in the outlying areas of Reunion Island.

The idea is to evaluate those action on health

Recruiting

Interested in participating?

Request Info

Key information

Conditions

HPV

Age range

30 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Cegidd Saint Paul, Saint-Paul, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged 30 to 65,
In a vulnerable situation (beneficiary of a state or departmental social service, or referred by a charity),
Resident in one of the two municipalities targeted by the study,
Supported by the social services of one of the two municipalities targeted by the study,
Having agreed to participate in sexual health awareness meetings organized on site

Exclusion criteria

Refusing to participate in the study
Having had a hysterectomy

Treatment and study plan

Public health workshop in community

Other

Cervical cancer screening awareness workshops, conducted in small groups through focus groups.

-2) Proposal for an HPV self-test (vaginal self-swab to detect high-risk HPV) as part of an individual consultation for participants who are not up-to-date with their cervical cancer screening.

Primary outcomes

Rate of women who complete cervical cancer screening after the community health intervention,

Time frame: 3 months

Rate of women aged 30 to 65 years living in vulnerable areas of Reunion Island who complete cervical cancer screening (HPV test or Pap smear) within 3months after the community health intervention, as documented in medical records or screening databases.

Study contacts

Contact information is provided by the study sponsor or research team.

Emmanuelle THORE, dr

CONTACT

[email protected]

+262 262 74 23 80

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Réunion

Other

Registry information

Acronym: ALONDEPISTHPV

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2028
First posted: Feb 27, 2026
Registry last updated: Feb 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting